D. E. Shaw & Co., Inc. Abb Vie Inc. Call Options Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

Call Options

29 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$163.84 - $199.33 $29.4 Million - $35.7 Million	-179,300 Reduced 27.9%	463,300 $91.5 Million
Q2 2024 Aug 14, 2024	BUY	$154.79 - $180.76 $12.8 Million - $14.9 Million	82,700 Added 14.77%	642,600 $110 Million
Q1 2024 May 15, 2024	SELL	$159.82 - $182.1 $99.1 Million - $113 Million	-619,900 Reduced 52.54%	559,900 $102 Million
Q4 2023 Feb 14, 2024	BUY	$137.6 - $154.97 $10.3 Million - $11.6 Million	75,000 Added 6.79%	1,179,800 $183 Million
Q3 2023 Nov 14, 2023	BUY	$133.59 - $154.65 $14.3 Million - $16.6 Million	107,200 Added 10.75%	1,104,800 $165 Million
Q2 2023 Aug 14, 2023	BUY	$132.51 - $164.9 $11.9 Million - $14.8 Million	89,600 Added 9.87%	997,600 $134 Million
Q1 2023 May 15, 2023	BUY	$144.61 - $166.54 $46.4 Million - $53.4 Million	320,800 Added 54.63%	908,000 $145 Million
Q4 2022 Feb 14, 2023	BUY	$138.31 - $165.87 $27.2 Million - $32.6 Million	196,600 Added 50.33%	587,200 $95 Million
Q3 2022 Nov 14, 2022	SELL	$134.21 - $153.93 $18.1 Million - $20.8 Million	-135,100 Reduced 25.7%	390,600 $52.4 Million
Q2 2022 Aug 15, 2022	SELL	$137.62 - $174.96 $16.7 Million - $21.2 Million	-121,200 Reduced 18.74%	525,700 $80.5 Million
Q1 2022 May 16, 2022	BUY	$131.98 - $163.75 $38.9 Million - $48.3 Million	295,100 Added 83.88%	646,900 $105 Million
Q4 2021 Feb 14, 2022	BUY	$107.43 - $135.93 $7.54 Million - $9.54 Million	70,200 Added 24.93%	351,800 $47.6 Million
Q3 2021 Nov 15, 2021	SELL	$106.4 - $120.78 $16 Million - $18.2 Million	-150,600 Reduced 34.84%	281,600 $30.4 Million
Q2 2021 Aug 16, 2021	BUY	$105.21 - $117.21 $11.5 Million - $12.8 Million	109,600 Added 33.97%	432,200 $48.7 Million
Q1 2021 May 17, 2021	SELL	$102.3 - $112.62 $29.8 Million - $32.8 Million	-291,400 Reduced 47.46%	322,600 $34.9 Million
Q4 2020 Feb 16, 2021	BUY	$80.49 - $108.67 $7.48 Million - $10.1 Million	92,900 Added 17.83%	614,000 $65.8 Million
Q3 2020 Nov 16, 2020	SELL	$85.91 - $100.83 $32.3 Million - $37.9 Million	-375,600 Reduced 41.89%	521,100 $45.6 Million
Q2 2020 Aug 14, 2020	BUY	$73.37 - $98.18 $47.7 Million - $63.8 Million	650,000 Added 263.48%	896,700 $88 Million
Q1 2020 May 15, 2020	SELL	$64.5 - $97.79 $39.8 Million - $60.3 Million	-616,300 Reduced 71.41%	246,700 $18.8 Million
Q4 2019 Feb 14, 2020	BUY	$72.13 - $90.25 $40 Million - $50 Million	554,100 Added 179.38%	863,000 $76.4 Million
Q3 2019 Nov 14, 2019	BUY	$62.98 - $75.72 $14.7 Million - $17.7 Million	234,000 Added 312.42%	308,900 $23.4 Million
Q2 2019 Aug 14, 2019	BUY	$65.7 - $83.98 $1.77 Million - $2.26 Million	26,900 Added 56.04%	74,900 $5.45 Million
Q1 2019 May 15, 2019	SELL	$77.14 - $90.79 $22.2 Million - $26.2 Million	-288,400 Reduced 85.73%	48,000 $3.87 Million
Q4 2018 Feb 14, 2019	SELL	$77.85 - $96.01 $7.61 Million - $9.39 Million	-97,800 Reduced 22.52%	336,400 $31 Million
Q3 2018 Nov 14, 2018	BUY	$88.91 - $98.84 $18.4 Million - $20.4 Million	206,500 Added 90.69%	434,200 $41.1 Million
Q2 2018 Aug 14, 2018	SELL	$89.78 - $106.23 $987,580 - $1.17 Million	-11,000 Reduced 4.61%	227,700 $21.1 Million
Q1 2018 May 15, 2018	SELL	$92.01 - $123.21 $570,462 - $763,902	-6,200 Reduced 2.53%	238,700 $22.6 Million
Q4 2017 Feb 14, 2018	SELL	$89.56 - $98.21 $16.8 Million - $18.5 Million	-188,100 Reduced 43.44%	244,900 $23.7 Million
Q3 2017 Nov 14, 2017	BUY	$69.85 - $89.22 $30.2 Million - $38.6 Million	433,000	433,000 $38.5 Million

Others Institutions Holding ABBV

# of Institutions

3,846

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $304B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account